289 related articles for article (PubMed ID: 16039909)
1. T Lymphocytes transduced with a lentiviral vector expressing F12-Vif are protected from HIV-1 infection in an APOBEC3G-independent manner.
Vallanti G; Lupo R; Federico M; Mavilio F; Bovolenta C
Mol Ther; 2005 Oct; 12(4):697-706. PubMed ID: 16039909
[TBL] [Abstract][Full Text] [Related]
2. Functional domains of APOBEC3G required for antiviral activity.
Li J; Potash MJ; Volsky DJ
J Cell Biochem; 2004 Jun; 92(3):560-72. PubMed ID: 15156567
[TBL] [Abstract][Full Text] [Related]
3. Isolation of a human gene that inhibits HIV-1 infection and is suppressed by the viral Vif protein.
Sheehy AM; Gaddis NC; Choi JD; Malim MH
Nature; 2002 Aug; 418(6898):646-50. PubMed ID: 12167863
[TBL] [Abstract][Full Text] [Related]
4. A new approach to an AIDS vaccine: creating antibodies to HIV vif will enable apobec3G to turn HIV-infection into a benign problem.
Jeffrey Fessel W
Med Hypotheses; 2005; 64(2):261-3. PubMed ID: 15607551
[TBL] [Abstract][Full Text] [Related]
5. Vpr14-88-Apobec3G fusion protein is efficiently incorporated into Vif-positive HIV-1 particles and inhibits viral infection.
Ao Z; Yu Z; Wang L; Zheng Y; Yao X
PLoS One; 2008 Apr; 3(4):e1995. PubMed ID: 18414671
[TBL] [Abstract][Full Text] [Related]
6. Influence of primate lentiviral Vif and proteasome inhibitors on human immunodeficiency virus type 1 virion packaging of APOBEC3G.
Liu B; Yu X; Luo K; Yu Y; Yu XF
J Virol; 2004 Feb; 78(4):2072-81. PubMed ID: 14747572
[TBL] [Abstract][Full Text] [Related]
7. A single amino acid substitution in human APOBEC3G antiretroviral enzyme confers resistance to HIV-1 virion infectivity factor-induced depletion.
Xu H; Svarovskaia ES; Barr R; Zhang Y; Khan MA; Strebel K; Pathak VK
Proc Natl Acad Sci U S A; 2004 Apr; 101(15):5652-7. PubMed ID: 15054139
[TBL] [Abstract][Full Text] [Related]
8. HIV-1 Vif blocks the antiviral activity of APOBEC3G by impairing both its translation and intracellular stability.
Stopak K; de Noronha C; Yonemoto W; Greene WC
Mol Cell; 2003 Sep; 12(3):591-601. PubMed ID: 14527406
[TBL] [Abstract][Full Text] [Related]
9. gag, vif, and nef genes contribute to the homologous viral interference induced by a nonproducer human immunodeficiency virus type 1 (HIV-1) variant: identification of novel HIV-1-inhibiting viral protein mutants.
D'Aloja P; Olivetta E; Bona R; Nappi F; Pedacchia D; Pugliese K; Ferrari G; Verani P; Federico M
J Virol; 1998 May; 72(5):4308-19. PubMed ID: 9557721
[TBL] [Abstract][Full Text] [Related]
10. Population level analysis of human immunodeficiency virus type 1 hypermutation and its relationship with APOBEC3G and vif genetic variation.
Pace C; Keller J; Nolan D; James I; Gaudieri S; Moore C; Mallal S
J Virol; 2006 Sep; 80(18):9259-69. PubMed ID: 16940537
[TBL] [Abstract][Full Text] [Related]
11. Species-specific exclusion of APOBEC3G from HIV-1 virions by Vif.
Mariani R; Chen D; Schröfelbauer B; Navarro F; König R; Bollman B; Münk C; Nymark-McMahon H; Landau NR
Cell; 2003 Jul; 114(1):21-31. PubMed ID: 12859895
[TBL] [Abstract][Full Text] [Related]
12. New insights into the role of Vif in HIV-1 replication.
Schröfelbauer B; Yu Q; Landau NR
AIDS Rev; 2004; 6(1):34-9. PubMed ID: 15168739
[TBL] [Abstract][Full Text] [Related]
13. HIV-1 Vif protein blocks the cytidine deaminase activity of B-cell specific AID in E. coli by a similar mechanism of action.
Santa-Marta M; Aires da Silva F; Fonseca AM; Rato S; Goncalves J
Mol Immunol; 2007 Jan; 44(4):583-90. PubMed ID: 16580072
[TBL] [Abstract][Full Text] [Related]
14. HIV-1 Vif protein binds the editing enzyme APOBEC3G and induces its degradation.
Marin M; Rose KM; Kozak SL; Kabat D
Nat Med; 2003 Nov; 9(11):1398-403. PubMed ID: 14528301
[TBL] [Abstract][Full Text] [Related]
15. Broad antiretroviral defence by human APOBEC3G through lethal editing of nascent reverse transcripts.
Mangeat B; Turelli P; Caron G; Friedli M; Perrin L; Trono D
Nature; 2003 Jul; 424(6944):99-103. PubMed ID: 12808466
[TBL] [Abstract][Full Text] [Related]
16. HIV-1 Vif and APOBEC3G: multiple roads to one goal.
Goncalves J; Santa-Marta M
Retrovirology; 2004 Sep; 1():28. PubMed ID: 15383144
[TBL] [Abstract][Full Text] [Related]
17. The antiretroviral enzyme APOBEC3G is degraded by the proteasome in response to HIV-1 Vif.
Sheehy AM; Gaddis NC; Malim MH
Nat Med; 2003 Nov; 9(11):1404-7. PubMed ID: 14528300
[TBL] [Abstract][Full Text] [Related]
18. Vif overcomes the innate antiviral activity of APOBEC3G by promoting its degradation in the ubiquitin-proteasome pathway.
Mehle A; Strack B; Ancuta P; Zhang C; McPike M; Gabuzda D
J Biol Chem; 2004 Feb; 279(9):7792-8. PubMed ID: 14672928
[TBL] [Abstract][Full Text] [Related]
19. Cellular APOBEC3G restricts HIV-1 infection in resting CD4+ T cells.
Chiu YL; Soros VB; Kreisberg JF; Stopak K; Yonemoto W; Greene WC
Nature; 2005 May; 435(7038):108-14. PubMed ID: 15829920
[TBL] [Abstract][Full Text] [Related]
20. Human immunodeficiency virus type 1 Vif inhibits packaging and antiviral activity of a degradation-resistant APOBEC3G variant.
Opi S; Kao S; Goila-Gaur R; Khan MA; Miyagi E; Takeuchi H; Strebel K
J Virol; 2007 Aug; 81(15):8236-46. PubMed ID: 17522211
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]